|
Sep 30
|
Adicet Bio to Present at the American Society of Gene & Cell Therapy’s (ASGCT) 2024 Advancing Gene + Cell Therapies for Cancer Conference
|
|
Sep 30
|
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
|
|
Aug 27
|
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
|
Aug 1
|
Adicet Bio to Participate in Upcoming Investor Conferences
|
|
Jul 25
|
Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds?
|
|
Jun 24
|
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
|
|
Jun 10
|
We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
|
|
May 14
|
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
|
|
May 14
|
Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
|
|
May 7
|
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
|
|
Apr 22
|
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
|
|
Apr 8
|
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
|
|
Mar 21
|
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?
|
|
Mar 19
|
Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
|
|
Mar 11
|
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
|
|
Jan 25
|
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
|
|
Jan 23
|
Adicet Bio, Inc. Announces Pricing of Public Offering
|
|
Jan 22
|
Adicet Bio, Inc. Announces Proposed Public Offering
|
|
Dec 10
|
Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting
|
|
Nov 8
|
Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates
|